Rein Therapeutics, Inc. Additional Paid in Capital, Common Stock
Rein Therapeutics, Inc. (RNTX) had Additional Paid in Capital, Common Stock of $423.58 million as of 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:AdditionalPaidInCapitalCommonStock · last filed 2026-08-14
- 2026-06-30: Additional Paid in Capital, Common Stock $423.58M.
- 2026-03-31: Additional Paid in Capital, Common Stock $373.64M.
- 2025-12-31: Additional Paid in Capital, Common Stock $373.13M.
- 2025-09-30: Additional Paid in Capital, Common Stock $370.42M.
| Period end | Additional Paid in Capital, Common Stock |
|---|---|
| 2026-06-30 | $423.58M 10-Q · filed 2026-08-14 |
| 2026-03-31 | $373.64M 10-Q · filed 2026-05-15 |
| 2025-12-31 | $373.13M 10-Q · filed 2026-08-14 |
| 2025-09-30 | $370.42M 10-Q · filed 2025-11-14 |
| 2025-06-30 | $366.64M 10-Q · filed 2025-08-14 |
| 2025-03-31 | $361.70M 10-Q · filed 2025-05-15 |
| 2024-12-31 | $360.70M 10-K · filed 2026-03-26 |
| 2024-09-30 | $360.56M 10-Q · filed 2024-11-14 |
| 2024-06-30 | $360.50M 10-Q · filed 2024-08-14 |
| 2024-03-31 | $340.34M 10-Q · filed 2024-05-15 |
| 2023-12-31 | $295.38M 10-K · filed 2025-04-07 |
| 2023-09-30 | $292.29M 10-Q · filed 2023-10-13 |
| 2023-06-30 | $292.06M 10-Q · filed 2023-08-11 |
| 2023-03-31 | $291.76M 10-Q · filed 2023-05-08 |
| 2022-12-31 | $291.37M 10-K · filed 2024-04-15 |
| 2022-09-30 | $290.94M 10-Q · filed 2022-11-01 |
| 2022-06-30 | $290.50M 10-Q · filed 2022-08-15 |
| 2022-03-31 | $289.97M 10-Q · filed 2022-05-05 |
| 2021-12-31 | $289.28M 10-K · filed 2023-03-20 |
| 2021-09-30 | $288.67M 10-Q · filed 2021-11-12 |
| 2021-06-30 | $287.99M 10-Q · filed 2021-08-11 |
| 2021-03-31 | $287.60M 10-Q · filed 2021-05-11 |
| 2020-12-31 | $231.41M 10-K · filed 2022-03-28 |
| 2020-09-30 | $226.72M 10-Q · filed 2020-11-12 |
| 2020-06-30 | $225.89M 10-Q · filed 2020-08-05 |
| 2020-03-31 | $214.63M 10-Q · filed 2020-05-11 |
| 2019-12-31 | $214.15M 10-K · filed 2021-03-24 |
| 2019-09-30 | $213.67M 10-Q · filed 2019-11-07 |
| 2019-06-30 | $213.08M 10-Q · filed 2019-08-06 |
| 2019-03-31 | $188.81M 10-Q · filed 2019-05-08 |
| 2018-12-31 | $188.08M 10-K · filed 2020-03-30 |
| 2018-09-30 | $187.48M 10-Q · filed 2018-11-07 |
| 2018-06-30 | $186.89M 10-Q · filed 2018-08-07 |
| 2018-03-31 | $185.54M 10-Q · filed 2018-05-09 |
| 2017-12-31 | $184.76M 10-K · filed 2019-03-29 |
| 2017-09-30 | $184.09M 10-Q · filed 2017-11-09 |
| 2017-06-30 | $3.04M 10-Q · filed 2017-08-10 |
| 2016-12-31 | $2.54M 10-K · filed 2018-04-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| HYPERION DEFI, INC. (HYPD) | United States | $0.065B | |
| XBiotech Inc. (XBIT) | United States | $0.066B | -1.56 |
| Skye Bioscience, Inc. (SKYE) | United States | $0.061B | -0.48 |
| CalciMedica, Inc. (CALC) | United States | $0.061B | -1.42 |
| TALPHERA, INC. (TLPH) | United States | $0.060B | |
| Boundless Bio, Inc. (BOLD) | United States | $0.059B | -0.88 |
| NOMAD POWER SOLUTIONS, INC. (NMAD) | United States | $0.058B | |
| Connect Biopharma Holdings Ltd (CNTB) | $0.069B | -2.17 | |
| Yarrow Bioscience, Inc. (YARW) | United States | $0.070B | |
| Annovis Bio, Inc. (ANVS) | United States | $0.056B | -1.58 |